Eli Lilly and Company (LLY)vsMeihua International Medical Technologies Co Ltd (MHUA)
LLY
Eli Lilly and Company
$1,131.42
-1.21%
HEALTHCARE · Cap: $1.01T
MHUA
Meihua International Medical Technologies Co Ltd
$7.61
0.00%
HEALTHCARE · Cap: $425.43M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 80582% more annual revenue ($72.25B vs $89.55M). LLY leads profitability with a 35.0% profit margin vs 10.3%. MHUA trades at a lower P/E of 0.3x. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
MHUA
Avoid34
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Attractively priced relative to earnings
Reasonable price relative to book value
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 32.4x book value
Smaller company, higher risk/reward
Weak financial health signals
Revenue declined 16.2%
Earnings declined 42.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bull Case : MHUA
The strongest argument for MHUA centers on P/E Ratio, Price/Book, Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 40.2x leaves little room for execution misses.
Bear Case : MHUA
The primary concerns for MHUA are Market Cap, Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
LLY profiles as a growth stock while MHUA is a declining play — different risk/reward profiles.
MHUA carries more volatility with a beta of 0.75 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 34/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Meihua International Medical Technologies Co Ltd
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Meihua International Medical Technologies Co., Ltd. is engaged in the manufacturing and marketing of medical consumables in the People's Republic of China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?